Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 2
2000 4
2001 6
2002 3
2003 15
2004 5
2005 12
2006 11
2007 11
2008 17
2009 8
2010 10
2011 12
2012 10
2013 15
2014 18
2015 15
2016 9
2017 15
2018 21
2019 13
2020 29
2021 32
2022 33
2023 40
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

330 results

Results by year

Filters applied: . Clear all
Page 1
Istradefylline.
[No authors listed] [No authors listed] 2021 Oct 18. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2021 Oct 18. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 34787989 Free Books & Documents. Review.
Istradefylline is an adenosine receptor antagonist that is used as adjunctive therapy to levodopa/carbidopa in patients with Parkinson disease experiencing difficulty with "off" episodes when motor symptoms breakthrough on treatment. Istradefylline has been associat …
Istradefylline is an adenosine receptor antagonist that is used as adjunctive therapy to levodopa/carbidopa in patients with Parkinso …
The role of istradefylline in the Parkinson's disease armamentarium.
Müller T. Müller T. Expert Opin Pharmacother. 2023 May;24(7):863-871. doi: 10.1080/14656566.2023.2201374. Epub 2023 Apr 18. Expert Opin Pharmacother. 2023. PMID: 37029952 Review.
EXPERT OPINION: Istradefylline is safe and well tolerated. Its efficacy was pronounced, when patients were on a lower chronic oral levodopa regimen. ...This review aims to define a broader role and potential of istradefylline for the treatment armamentarium of Parki …
EXPERT OPINION: Istradefylline is safe and well tolerated. Its efficacy was pronounced, when patients were on a lower chronic oral le …
Istradefylline for OFF Episodes in Parkinson's Disease: A US Perspective of Common Clinical Scenarios.
Isaacson SH, Betté S, Pahwa R. Isaacson SH, et al. Degener Neurol Neuromuscul Dis. 2022 Jul 23;12:97-109. doi: 10.2147/DNND.S245197. eCollection 2022. Degener Neurol Neuromuscul Dis. 2022. PMID: 35910426 Free PMC article. Review.
The effective management of OFF episodes remains an important unmet need for patients with Parkinson's disease (PD) who develop motor complications with long-term levodopa therapy. Istradefylline is a selective adenosine A(2A) receptor antagonist for the treatment of patie …
The effective management of OFF episodes remains an important unmet need for patients with Parkinson's disease (PD) who develop motor compli …
Istradefylline - a first generation adenosine A(2A) antagonist for the treatment of Parkinson's disease.
Jenner P, Mori A, Aradi SD, Hauser RA. Jenner P, et al. Expert Rev Neurother. 2021 Mar;21(3):317-333. doi: 10.1080/14737175.2021.1880896. Epub 2021 Feb 22. Expert Rev Neurother. 2021. PMID: 33507105 Review.
The relatively complicated clinical development of istradefylline was based on classically designed studies conducted in PD patients with motor fluctuations on an optimized regimen of levodopa plus adjunctive dopaminergic medications. ...Exploration of istradefylline …
The relatively complicated clinical development of istradefylline was based on classically designed studies conducted in PD patients …
Istradefylline for the treatment of Parkinson's disease: is it a promising strategy?
Torti M, Vacca L, Stocchi F. Torti M, et al. Expert Opin Pharmacother. 2018 Nov;19(16):1821-1828. doi: 10.1080/14656566.2018.1524876. Epub 2018 Oct 11. Expert Opin Pharmacother. 2018. PMID: 30232916 Review.
Istradefylline (ISD) is a new drug developed for the treatment of Parkinson's disease (PD). ...
Istradefylline (ISD) is a new drug developed for the treatment of Parkinson's disease (PD). ...
Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's disease.
Paton DM. Paton DM. Drugs Today (Barc). 2020 Feb;56(2):125-134. doi: 10.1358/dot.2020.56.2.3098156. Drugs Today (Barc). 2020. PMID: 32163528 Review.
., Ltd.) has been researching the possibility of finding drugs that affect adenosine receptors and that can be used successfully as additional drugs in the treatment of PD. Istradefylline is an adenosine A2A receptor antagonist that significantly reduces the "OFF" time and …
., Ltd.) has been researching the possibility of finding drugs that affect adenosine receptors and that can be used successfully as addition …
The safety of istradefylline for the treatment of Parkinson's disease.
Müller T. Müller T. Expert Opin Drug Saf. 2015 May;14(5):769-75. doi: 10.1517/14740338.2015.1014798. Epub 2015 Feb 13. Expert Opin Drug Saf. 2015. PMID: 25676023 Review.
Istradefylline easily crosses the blood-brain barrier and shows a high affinity to the human A2A receptor. ...EXPERT OPINION: Istradefylline was safe and well tolerated in clinical trials, which have focused on l-DOPA-treated PD patients. ...
Istradefylline easily crosses the blood-brain barrier and shows a high affinity to the human A2A receptor. ...EXPERT OPINION: Istr …
Istradefylline to Treat Patients with Parkinson's Disease Experiencing "Off" Episodes: A Comprehensive Review.
Berger AA, Winnick A, Welschmeyer A, Kaneb A, Berardino K, Cornett EM, Kaye AD, Viswanath O, Urits I. Berger AA, et al. Neurol Int. 2020 Dec 8;12(3):109-129. doi: 10.3390/neurolint12030017. Neurol Int. 2020. PMID: 33302331 Free PMC article. Review.
These periods, referred to as "off episodes", are characterized by increased symptoms and have a detrimental effect on quality of life and disability. Istradefylline, a novel adenosine A2A receptor antagonist, is indicated as a treatment addition to levodopa/carbidopa in p …
These periods, referred to as "off episodes", are characterized by increased symptoms and have a detrimental effect on quality of life and d …
Istradefylline Improves Impaired Smooth Pursuit Eye Movements in Parkinson's Disease.
Fujita Y, Kawaguchi E, Toyomoto T, Shirasaki H. Fujita Y, et al. Neurol Ther. 2023 Oct;12(5):1791-1798. doi: 10.1007/s40120-023-00509-1. Epub 2023 Jun 17. Neurol Ther. 2023. PMID: 37329392 Free PMC article.
Eye tracking data were obtained 4-8 weeks after initiation of istradefylline administration. Istradefylline increased smooth pursuit gain and the accuracy of smooth pursuit velocity, and tended to decrease saccade rates during pursuit. CONCLUSIONS: Istradefylline …
Eye tracking data were obtained 4-8 weeks after initiation of istradefylline administration. Istradefylline increased smooth p …
Istradefylline for the treatment of Parkinson's disease.
Park A, Stacy M. Park A, et al. Expert Opin Pharmacother. 2012 Jan;13(1):111-4. doi: 10.1517/14656566.2012.643869. Expert Opin Pharmacother. 2012. PMID: 22149371 Review.
INTRODUCTION: Despite several available therapeutic options to treat the symptoms of Parkinson's disease (PD), there are currently no agents that halt or slow the progression of disease. Istradefylline is a selective adenosine A(2A) antagonist that is currently of interest …
INTRODUCTION: Despite several available therapeutic options to treat the symptoms of Parkinson's disease (PD), there are currently no agents …
330 results

Searches related to "istradefylline"